{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:14:32Z","timestamp":1791231272407,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11202-x","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:58Z","timestamp":1761808258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks"],"prefix":"10.1007","volume":"53","author":[{"given":"Anirban Goutam","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abilash Valsala","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"3","key":"11202_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","volume":"27","author":"MX He","year":"2021","unstructured":"He MX et al (2021) Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 27(3):426\u2013433","journal-title":"Nat Med"},{"issue":"1","key":"11202_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ et al (2021) Prostate cancer. Nat Rev Dis Primers 7(1):9","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"11202_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711","journal-title":"Nat Rev Cancer"},{"key":"11202_CR4","doi-asserted-by":"crossref","unstructured":"Cheng X (2024) A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes (Basel) 15(7)","DOI":"10.3390\/genes15070903"},{"issue":"2","key":"11202_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127\u201337","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"23","key":"11202_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","volume":"92","author":"S Signoretti","year":"2000","unstructured":"Signoretti S et al (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92(23):1918\u20131925","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"11202_CR7","first-page":"3438","volume":"8","author":"G Di Lorenzo","year":"2002","unstructured":"Di Lorenzo G et al (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8(11):3438\u20133444","journal-title":"Clin Cancer Res"},{"issue":"19","key":"11202_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/cancers16193262","volume":"16","author":"N Mavingire","year":"2024","unstructured":"Mavingire N et al (2024) Revisiting HER2 in prostate cancer from an inclusive perspective: from biomarkers to Omics. Cancers (Basel) 16(19):25","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11202_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1309\/VXKK-YVRH-9B11-YDPT","volume":"116","author":"DM Reese","year":"2001","unstructured":"Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D (2001) HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116(2):234\u2013239","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"11202_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","volume":"77","author":"KC Day","year":"2017","unstructured":"Day KC et al (2017) HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res 77(1):74\u201385","journal-title":"Cancer Res"},{"issue":"6","key":"11202_CR11","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.3892\/ol.2016.5235","volume":"12","author":"N Sharifi","year":"2016","unstructured":"Sharifi N et al (2016) HER2 gene amplification in patients with prostate cancer: evaluating a CISH-based method. Oncol Lett 12(6):4651\u20134658","journal-title":"Oncol Lett"},{"issue":"5","key":"11202_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","volume":"16","author":"S Minner","year":"2010","unstructured":"Minner S et al (2010) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16(5):1553\u20131560","journal-title":"Clin Cancer Res"},{"issue":"4","key":"11202_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/cncr.10339","volume":"94","author":"MJ Morris","year":"2002","unstructured":"Morris MJ et al (2002) HER-2 profiling and targeting in prostate carcinoma. Cancer 94(4):980\u2013986","journal-title":"Cancer"},{"key":"11202_CR14","doi-asserted-by":"publisher","first-page":"152219","DOI":"10.1016\/j.anndiagpath.2023.152219","volume":"67","author":"F Estephan","year":"2023","unstructured":"Estephan F et al (2023) The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma. Ann Diagn Pathol 67:152219","journal-title":"Ann Diagn Pathol"},{"issue":"9","key":"11202_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.prp.2013.05.008","volume":"209","author":"EE Pala","year":"2013","unstructured":"Pala EE, Bayol U, Ozguzer A, Akman O (2013) HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest\u2122). Pathol Res Pract 209(9):548\u2013554","journal-title":"Pathol Res Pract"},{"key":"11202_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.humpath.2024.05.002","volume":"148","author":"JM Navarro Sanchez","year":"2024","unstructured":"Navarro Sanchez JM et al (2024) Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas. Hum Pathol 148:51\u201359","journal-title":"Hum Pathol"},{"issue":"2","key":"11202_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semradonc.2007.10.006","volume":"18","author":"D Voduc","year":"2008","unstructured":"Voduc D, Kenney C, Nielsen TO (2008) Tissue microarrays in clinical oncology. Semin Radiat Oncol 18(2):89\u201397","journal-title":"Semin Radiat Oncol"},{"key":"11202_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers13236014","volume":"13","author":"D Maillet","year":"2021","unstructured":"Maillet D et al (2021) Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 13:23","journal-title":"Cancers (Basel)"},{"issue":"3","key":"11202_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3892\/mco.2021.2347","volume":"15","author":"GA Peixoto","year":"2021","unstructured":"Peixoto GA et al (2021) The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue. Mol Clin Oncol 15(3):185","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"11202_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099525","volume":"9","author":"J Tome-Garcia","year":"2014","unstructured":"Tome-Garcia J, Li D, Ghazaryan S, Shu L, Wu L (2014) ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells. PLoS ONE 9(6):e99525","journal-title":"PLoS ONE"},{"issue":"24","key":"11202_CR21","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","volume":"81","author":"V Gil","year":"2021","unstructured":"Gil V et al (2021) HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res 81(24):6207\u20136218","journal-title":"Cancer Res"},{"issue":"2","key":"11202_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/03915603221118471","volume":"90","author":"A Abhishek","year":"2023","unstructured":"Abhishek A, Sarkar D, Kumar Pal D (2023) Expression of HER2\/NEU in newly diagnosed metastatic carcinoma prostate on TRUS biopsy specimen and its clinical correlation and progression. Urologia 90(2):244\u2013247","journal-title":"Urologia"},{"issue":"5","key":"11202_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ccr.2004.09.031","volume":"6","author":"IK Mellinghoff","year":"2004","unstructured":"Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2\/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6(5):517\u201327","journal-title":"Cancer Cell"},{"issue":"8","key":"11202_CR24","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/cncr.10839","volume":"95","author":"KM Sanchez","year":"2002","unstructured":"Sanchez KM et al (2002) Evaluation of HER-2\/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer 95(8):1650\u20131655","journal-title":"Cancer"},{"issue":"9","key":"11202_CR25","first-page":"2643","volume":"7","author":"I Osman","year":"2001","unstructured":"Osman I et al (2001) HER-2\/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7(9):2643\u20132647","journal-title":"Clin Cancer Res"},{"issue":"3","key":"11202_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/6495","volume":"5","author":"N Craft","year":"1999","unstructured":"Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase. Nat Med 5(3):280\u2013285","journal-title":"Nat Med"},{"issue":"2","key":"11202_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/exmp.1999.2242","volume":"66","author":"HF Mark","year":"1999","unstructured":"Mark HF et al (1999) Fluorescence in situ hybridization study of HER-2\/neu oncogene amplification in prostate cancer. Exp Mol Pathol 66(2):170\u2013178","journal-title":"Exp Mol Pathol"},{"issue":"7","key":"11202_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0046-8177(97)90157-X","volume":"28","author":"JS Ross","year":"1997","unstructured":"Ross JS et al (1997) HER-2\/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 28(7):827\u2013833","journal-title":"Hum Pathol"},{"issue":"21","key":"11202_CR29","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.18632\/oncotarget.2655","volume":"5","author":"K Mujoo","year":"2014","unstructured":"Mujoo K, Choi BK, Huang Z, Zhang N, An Z (2014) Regulation of ERBB3\/HER3 signaling in cancer. Oncotarget 5(21):10222\u201310236","journal-title":"Oncotarget"},{"key":"11202_CR30","first-page":"14","volume":"7","author":"H Zeng","year":"2024","unstructured":"Zeng H, Wang W, Zhang L, Lin Z (2024) HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs. Cancer Drug Resist 7:14","journal-title":"Cancer Drug Resist"},{"key":"11202_CR31","doi-asserted-by":"crossref","unstructured":"Zhu ML, Kyprianou N Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15(4):841\u2013849","DOI":"10.1677\/ERC-08-0084"},{"issue":"10","key":"11202_CR32","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1073\/pnas.96.10.5458","volume":"96","author":"S Yeh","year":"1999","unstructured":"Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999) From HER2\/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96(10):5458\u20135463","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11202_CR33","doi-asserted-by":"crossref","unstructured":"Grossmann ME, Huang H, Tindall DJ Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687\u20131697","DOI":"10.1093\/jnci\/93.22.1687"},{"issue":"12","key":"11202_CR34","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/bjc.2011.163","volume":"104","author":"R Mukherjee","year":"2011","unstructured":"Mukherjee R et al (2011) Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer 104(12):1920\u20131928","journal-title":"Br J Cancer"},{"issue":"6","key":"11202_CR35","first-page":"2883","volume":"7","author":"B Xu","year":"2014","unstructured":"Xu B, Tang G, Xiao C, Wang L, Yang Q, Sun Y (2014) Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers. Int J Clin Exp Pathol 7(6):2883\u20132893","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"11202_CR36","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/0008-5472.CAN-04-4292","volume":"65","author":"Y Liu","year":"2005","unstructured":"Liu Y et al (2005) Inhibition of HER-2\/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65(8):3404\u20133409","journal-title":"Cancer Res"},{"issue":"5","key":"11202_CR37","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/1078-0432.CCR-04-1158","volume":"11","author":"CW Gregory","year":"2005","unstructured":"Gregory CW et al (2005) Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11(5):1704\u20131712","journal-title":"Clin Cancer Res"},{"issue":"14","key":"11202_CR38","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-09-4440","volume":"70","author":"L Chen","year":"2010","unstructured":"Chen L et al (2010) Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res 70(14):5994\u20136003","journal-title":"Cancer Res"},{"issue":"2","key":"11202_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1476-5586(03)80001-5","volume":"5","author":"SS El Sheikh","year":"2003","unstructured":"El Sheikh SS, Domin J, Abel P, Stamp G, Lalani N (2003) Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 5(2):99\u2013109","journal-title":"Neoplasia"},{"issue":"19","key":"11202_CR40","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1158\/1078-0432.CCR-11-1548","volume":"17","author":"L Chen","year":"2011","unstructured":"Chen L et al (2011) Dual EGFR\/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17(19):6218\u20136228","journal-title":"Clin Cancer Res"},{"issue":"5","key":"11202_CR41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/15384047.2020.1727702","volume":"21","author":"A Rossini","year":"2020","unstructured":"Rossini A et al (2020) Combined targeting of EGFR and HER2 against prostate cancer stem cells. Cancer Biol Ther 21(5):463\u2013475","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"11202_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41416-019-0496-4","volume":"121","author":"MK Jathal","year":"2019","unstructured":"Jathal MK et al (2019) Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. Br J Cancer 121(3):237\u2013248","journal-title":"Br J Cancer"},{"issue":"5","key":"11202_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5):575\u2013586","journal-title":"Cancer Cell"},{"issue":"1","key":"11202_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41388-023-02875-4","volume":"43","author":"KA Miller","year":"2024","unstructured":"Miller KA et al (2024) PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. Oncogene 43(1):22\u201334","journal-title":"Oncogene"},{"issue":"4","key":"11202_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pros.20065","volume":"60","author":"A Ziada","year":"2004","unstructured":"Ziada A et al (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60(4):332\u2013337","journal-title":"Prostate"},{"issue":"10","key":"11202_CR46","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/cncr.20228","volume":"100","author":"PN Lara Jr.","year":"2004","unstructured":"Lara PN Jr. et al (2004) Trastuzumab plus docetaxel in HER-2\/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10):2125\u20132131","journal-title":"Cancer"},{"issue":"2","key":"11202_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.urolonc.2011.01.002","volume":"31","author":"G Liu","year":"2013","unstructured":"Liu G et al (2013) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31(2):211\u2013218","journal-title":"Urol Oncol"},{"issue":"13","key":"11202_CR48","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","volume":"78","author":"A Ruiz-Saenz","year":"2018","unstructured":"Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM (2018) HER2 Amplification in Tumors Activates PI3K\/Akt Signaling Independent of HER3. Cancer Res 78(13):3645\u20133658","journal-title":"Cancer Res"},{"issue":"15","key":"11202_CR49","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-08-0125","volume":"15","author":"D Sarker","year":"2009","unstructured":"Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K\/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15):4799\u20134805","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11202_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1006\/excr.1999.4690","volume":"253","author":"ES Kandel","year":"1999","unstructured":"Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine\/threonine kinase Akt\/PKB. Exp Cell Res 253(1):210\u2013229","journal-title":"Exp Cell Res"},{"issue":"5338","key":"11202_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.278.5338.687","volume":"278","author":"L del Peso","year":"1997","unstructured":"del Peso L, Gonz\u00e1lez-Garc\u00eda M, Page C, Herrera R, Nu\u00f1ez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338):687\u2013689","journal-title":"Science"},{"issue":"5392","key":"11202_CR52","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","volume":"282","author":"MH Cardone","year":"1998","unstructured":"Cardone MH et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318\u20131321","journal-title":"Science"},{"issue":"6","key":"11202_CR53","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet A et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857\u2013868","journal-title":"Cell"},{"issue":"12","key":"11202_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB (2020) The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 21(12):25","journal-title":"Int J Mol Sci"},{"issue":"24","key":"11202_CR55","first-page":"6841","volume":"60","author":"Y Wen","year":"2000","unstructured":"Wen Y et al (2000) HER-2\/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60(24):6841\u20136845","journal-title":"Cancer Res"},{"issue":"4","key":"11202_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15(4):222\u2013234","journal-title":"Nat Rev Urol"},{"issue":"39","key":"11202_CR57","doi-asserted-by":"publisher","first-page":"41976","DOI":"10.18632\/oncotarget.5659","volume":"6","author":"W Qi","year":"2015","unstructured":"Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D (2015) Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget 6(39):41976\u201341987","journal-title":"Oncotarget"},{"issue":"4","key":"11202_CR58","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/ijms24032046","volume":"24","author":"E Tortorella","year":"2023","unstructured":"Tortorella E, Giantulli S, Sciarra A, Silvestri I (2023) AR and PI3K\/AKT in prostate cancer: a tale of two interconnected pathways. Int J Mol Sci 24(4):2046","journal-title":"Int J Mol Sci"},{"issue":"3","key":"11202_CR59","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/1878-0261.13577","volume":"18","author":"T Sugawara","year":"2024","unstructured":"Sugawara T et al (2024) Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol 18(3):726\u2013742","journal-title":"Mol Oncol"},{"issue":"3","key":"11202_CR60","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","volume":"17","author":"M Hashemi","year":"2023","unstructured":"Hashemi M et al (2023) Targeting PI3K\/Akt signaling in prostate cancer therapy. J Cell Commun Signal 17(3):423\u2013443","journal-title":"J Cell Commun Signal"},{"issue":"7","key":"11202_CR61","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/sj.bjc.6605571","volume":"102","author":"IH Koumakpayi","year":"2010","unstructured":"Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F (2010) Hierarchical clustering of immunohistochemical analysis of the activated ErbB\/PI3K\/Akt\/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer 102(7):1163\u20131173","journal-title":"Br J Cancer"},{"issue":"5","key":"11202_CR62","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/pros.20903","volume":"69","author":"AM DeHaan","year":"2009","unstructured":"DeHaan AM, Wolters NM, Keller ET, Ignatoski KM (2009) EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 69(5):528\u2013537","journal-title":"Prostate"},{"issue":"12","key":"11202_CR63","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.bjc.6605376","volume":"101","author":"AM Traish","year":"2009","unstructured":"Traish AM, Morgentaler A (2009) Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 101(12):1949\u20131956","journal-title":"Br J Cancer"},{"issue":"2","key":"11202_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/pros.20234","volume":"65","author":"C Le Page","year":"2005","unstructured":"Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells Prostate 65(2):130\u2013140","journal-title":"Prostate"},{"issue":"8","key":"11202_CR65","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/onc.2009.410","volume":"29","author":"EC Merkhofer","year":"2010","unstructured":"Merkhofer EC, Cogswell P, Baldwin AS (2010) Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29(8):1238\u20131248","journal-title":"Oncogene"},{"issue":"3","key":"11202_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6605490","volume":"102","author":"X Lu","year":"2010","unstructured":"Lu X, Kang Y (2010) Epidermal growth factor signalling and bone metastasis. Br J Cancer 102(3):457\u2013461","journal-title":"Br J Cancer"},{"key":"11202_CR67","doi-asserted-by":"crossref","unstructured":"Schramek D, Penninger JM (2011) The many roles of RANKL-RANK signaling in bone, breast and cancer. IBMS BoneKEy 8(5)","DOI":"10.1138\/20110512"},{"issue":"7335","key":"11202_CR68","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan W et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548\u2013553","journal-title":"Nature"},{"issue":"5","key":"11202_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.31083\/j.fbl2905184","volume":"29","author":"KS Mohammad","year":"2024","unstructured":"Mohammad KS, Akhund SA (2024) From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis. Front Biosci 29(5):184","journal-title":"Front Biosci"},{"issue":"2","key":"11202_CR70","doi-asserted-by":"publisher","first-page":"e31919","DOI":"10.1371\/journal.pone.0031919","volume":"7","author":"M Mimeault","year":"2012","unstructured":"Mimeault M, Johansson SL, Batra SK (2012) Pathobiological implications of the expression of EGFR, pAkt, NF-\u03baB and MIC-1 in prostate cancer stem cells and their progenies. PLoS ONE 7(2):e31919","journal-title":"PLoS ONE"},{"issue":"18","key":"11202_CR71","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1002\/cncr.31600","volume":"124","author":"P Saintigny","year":"2018","unstructured":"Saintigny P et al (2018) Frequent PTEN loss and differential HER2\/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124(18):3693\u20133705","journal-title":"Cancer"},{"issue":"39","key":"11202_CR72","doi-asserted-by":"publisher","first-page":"16392","DOI":"10.1073\/pnas.1101263108","volume":"108","author":"I Ahmad","year":"2011","unstructured":"Ahmad I et al (2011) HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 108(39):16392\u201316397","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11202_CR73","doi-asserted-by":"crossref","unstructured":"Wilkinson S et al (2024) Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition. medrxiv","DOI":"10.1101\/2024.02.09.24302395"},{"issue":"10","key":"11202_CR74","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.7150\/jca.112954","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Zhao W, Wang D, Chen L, Feng Y, Sun P (2025) Neuregulin-1 correlates to early castration-resistant prostate cancer after prostate cancer patients receiving androgen deprivation therapy. J Cancer 16(10):3261\u20133269","journal-title":"J Cancer"},{"issue":"19","key":"11202_CR75","first-page":"5485","volume":"62","author":"N Mendoza","year":"2002","unstructured":"Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62(19):5485\u20135488","journal-title":"Cancer Res"},{"key":"11202_CR76","volume-title":"Interaction between prostatic acid phosphatase and ErbB-2\/HER2\/Neu regulates human prostate cancer cell growth and androgen responsiveness","author":"T-C Meng","year":"1999","unstructured":"Meng T-C (1999) Interaction between prostatic acid phosphatase and ErbB-2\/HER2\/Neu regulates human prostate cancer cell growth and androgen responsiveness. University of Nebraska Medical Center"},{"issue":"2","key":"11202_CR77","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","volume":"38","author":"Z Zhang","year":"2020","unstructured":"Zhang Z et al (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell 38(2):279\u2013296","journal-title":"Cancer Cell"},{"issue":"1","key":"11202_CR78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G (2021) Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 14(1):20","journal-title":"J Hematol Oncol"},{"issue":"7","key":"11202_CR79","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107(7):1039\u20131046","journal-title":"Cancer Sci"},{"issue":"2","key":"11202_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/sj.bjc.6603553","volume":"96","author":"ME Legrier","year":"2007","unstructured":"Legrier ME et al (2007) Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 96(2):269\u2013276","journal-title":"Br J Cancer"},{"key":"11202_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z et al (2019) Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab Deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur J Med Chem 183:111682","journal-title":"Eur J Med Chem"},{"issue":"4","key":"11202_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040800","volume":"16","author":"BS Zimmerman","year":"2024","unstructured":"Zimmerman BS, Esteva FJ (2024) Next-generation HER2-targeted antibody\u2013drug conjugates in breast cancer. Cancers (Basel) 16(4):800","journal-title":"Cancers (Basel)"},{"issue":"13_Supplement","key":"11202_CR83","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1538-7445.AM2019-395","volume":"79","author":"JW Russo","year":"2019","unstructured":"Russo JW, Gao X, Einstein DJ, Bubley GJ, Balk SP (2019) Aberrant HER2 signaling is a therapeutic target in a subset of castration-resistant prostate cancer. Cancer Res 79(13_Supplement):395\u2013395","journal-title":"Cancer Res"},{"issue":"19","key":"11202_CR84","first-page":"4761","volume":"59","author":"DB Agus","year":"1999","unstructured":"Agus DB et al (1999) Response of prostate cancer to anti-Her-2\/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 59(19):4761\u20134764","journal-title":"Cancer Res"},{"key":"11202_CR85","volume":"41","author":"DB Agus","year":"2000","unstructured":"Agus DB, Scher H, Fox W, Higgins B, Maiese K, Akita R (2000) Differential anti-tumor effects of targeting distinct epitopes of the Her-2\/neu extracellular domain in xenograft models of prostate cancer. Proc Am Assoc Cancer Res 41:719","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"2","key":"11202_CR86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/72294","volume":"6","author":"X Xing","year":"2000","unstructured":"Xing X et al (2000) The ets protein PEA3 suppresses HER-2\/neu overexpression and inhibits tumorigenesis. Nat Med 6(2):189\u201395","journal-title":"Nat Med"},{"issue":"3","key":"11202_CR87","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.2006.07.0888","volume":"25","author":"JS de Bono","year":"2007","unstructured":"de Bono JS et al (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25(3):257\u2013262","journal-title":"J Clin Oncol"},{"issue":"4","key":"11202_CR88","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4):317\u2013328","journal-title":"Cancer Cell"},{"issue":"11","key":"11202_CR89","first-page":"3132","volume":"62","author":"PN M\u00fcnster","year":"2002","unstructured":"M\u00fcnster PN, Marchion DC, Basso AD, Rosen N (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3\u2019-kinase-AKT-dependent pathway. Cancer Res 62(11):3132\u20133137","journal-title":"Cancer Res"},{"issue":"4","key":"11202_CR90","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843\u2013851","journal-title":"Mol Ther"},{"key":"11202_CR91","doi-asserted-by":"crossref","unstructured":"Shabaneh TB et al (2024) Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J Immunother Cancer 12(2)","DOI":"10.1136\/jitc-2023-008566"},{"issue":"1","key":"11202_CR92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","volume":"31","author":"YE Whang","year":"2013","unstructured":"Whang YE et al (2013) A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 31(1):82\u20136","journal-title":"Urol Oncol"},{"issue":"6","key":"11202_CR93","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2006.07.0649","volume":"25","author":"DB Agus","year":"2007","unstructured":"Agus DB et al (2007) Efficacy and safety of single-agent Pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25(6):675\u2013681","journal-title":"J Clin Oncol"},{"key":"11202_CR94","doi-asserted-by":"publisher","first-page":"101642","DOI":"10.1016\/j.tranon.2023.101642","volume":"31","author":"K Yumoto","year":"2023","unstructured":"Yumoto K et al (2023) HER2 as a potential therapeutic target on quiescent prostate cancer cells. Transl Oncol 31:101642","journal-title":"Transl Oncol"},{"issue":"2","key":"11202_CR95","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3816\/CGC.2004.n.021","volume":"3","author":"PA Davol","year":"2004","unstructured":"Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG (2004) Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer 3(2):112\u2013121","journal-title":"Clin Prostate Cancer"},{"issue":"2","key":"11202_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ et al (2018) Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA\u2009+\u2009metastatic prostate cancer. Oncoimmunology 7(2):e1380764","journal-title":"Oncoimmunology"},{"issue":"33","key":"11202_CR97","doi-asserted-by":"publisher","first-page":"52810","DOI":"10.18632\/oncotarget.10547","volume":"7","author":"JN Graff","year":"2016","unstructured":"Graff JN et al (2016) Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7(33):52810\u201352817","journal-title":"Oncotarget"},{"key":"11202_CR98","doi-asserted-by":"crossref","unstructured":"Huang SP et al (2021) NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer. Biomedicines 9(5)","DOI":"10.3390\/biomedicines9050528"},{"key":"11202_CR99","doi-asserted-by":"crossref","unstructured":"Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN (2023) Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers 15(6)","DOI":"10.3390\/cancers15061845"},{"key":"11202_CR100","doi-asserted-by":"crossref","unstructured":"Enikeev D, Morozov A, Babaevskaya D, Bazarkin A, Malavaud B (2022) A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis. Cancers 14(15)","DOI":"10.3390\/cancers14153802"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11202-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:04:25Z","timestamp":1761811465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11202"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11202-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31"}}